

"Express Mail" mailing label number EL 832954734 US

Date of Deposit FEB. 01, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

QUEEN THOMAS Queen Thomas
Printed Name Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : GADSKI, Robert Alan, et al.)
)
For : SUBSTITUTED AZEPINES AS HISTAMINE)
H3 RECEPTOR ANTAGONISTS,)
PREPARATION AND THERAPEUTIC USES)
)
Docket No. : X-14988)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



Dan L. Wood
Attorney for Applicants
Registration No. 48,613
Phone: 317-277-3366

Eli Lilly and Company
Patent Division/DLW
P.O. Box 6288
Indianapolis, Indiana 46206-6288

February 1, 2005

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-14988	Serial No
	Applicants GADSKI, Robert Alan, et al.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 4,210,749	July 1, 1980	Shetty	
	AB	US 2001/0049367	December 6, 2001	Bennani, et al.	
	AC	US 2002/0035103	March 21, 2002	Bennani, et al.	
	AD	US 2002/0111340	August 15, 2002	Bennani, et al.	
	AE	US 2002/0137931	September 26, 2002	Bennani, et al.	
	AF	US 2002/0169188	November 14, 2002	Cowart, et al.	
	AG	US 6,610,721	August 26, 2003	Andersen, et al.	
	AH	US 2003/158177	August 21, 2003	Ishihara, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	BA	EP 1 057 814	December 6, 2000	Meiji Seika Kaisha, Ltd.	
	BB	WO 98/46590	October 22, 1998	Takeda Chemical Industries, Ltd.	
	BC	WO 03/006466	January 23, 2003	Pharmacia & Upjohn Co.	
	BD	EP 0 982 300	March 1, 2000	Societe Civile Bioprojet	
	BE	WO 93/03015	February 18, 1993	Smith-Kline Beecham, Corp.	
	BF	EP 1 283199	February 12, 2003	Takeda Chemical Industries, Ltd.	
	BG	WO 00/06254	February 10, 2000	Societe Civile Bioprojet	
	BH	WO 03/064411	August 7, 2003	Novo Nordisk A/S	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.
	CA	VEJDELEK, Z.J. et al., "Benzocycloheptenes and heterocyclic analogues as potential drugs. X. Derivatives of 2-Amino and 2-Hydroxy-6,7,8,9-tetrahydro-5H-benzocycloheptene" <i>Collection of Czechoslovak Chemical Communications, Academic Press, London, GB, Vol. 38, 1973, pp 2989-2995.</i>

FORM PTO 1449 (modified)	Atty. Docket No. X-14988	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants GADSKI, Robert Alan, et al.	
	Filing Date	Group

	CB	ODA, T. et al, "Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes" <i>Journal of Biological Chemistry, American Society of Biological Chemists</i> , Baltimore, MD, US, Vol. 275, No. 47, 24 November 2000, pp 36781-36786.
	CC	SEVERINE MORISSET ET AL., High constitutive activity of native H ₃ receptors regulates histamine neurons in brain, <i>Nature</i> , 860-864, 14 December 2000, Vol. 408
	CD	IAN D. LINNEY ET AL., Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H ₃ Receptor Antagonists, <i>J. Med. Chem.</i> , 2362-2370, 2000, Vol 43
	CE	HENK VAN DER GOOT ET AL., Selective ligands as tools to study histamine receptors, <i>Eur. J. Med. Chem.</i> , 5-20, 2000, Vol. 35
	CF	HOLGER STARK ET AL., Analogues and Derivatives of Ciproxifan, a Novel Prototype for Generating Potent Histamine H ₃ -Receptor Antagonists, <i>Bioorganic & Medicinal Chemistry Letters</i> 2379-2382, 2000, Vol. 10
	CG	ALBERT D. WINDHORST ET AL., Characterization of the Binding Site of the Histamine H ₃ Receptr. 2. Synthesis, in Vitro Pharmacology, and QSAR of a Series of Monosubstituted Benzyl Analogues of Thioperamide, <i>J. Med. Chem.</i> 1754-1761, 2000, Vol. 43
	CH	ASTRID SASSE ET AL., New Histamine H ₃ -Receptor Ligands of the proxifan Series: Imoproxifan and Other Sleective Antagonists with High Oral in Vivo Potency, <i>J. Med. Chem.</i> , 3335-3343, 2000, Vol. 43
	CI	HOLGER STARK ET AL., Novel Histamine H ₃ -Receptor Antagonists with Carbonyl-Substituted 4-(3-(Phenoxy)propyl)-1H-imidazole Structures like Ciproxifan and Related Compounds, <i>J. Med. Chem.</i> , 3987-3994, 2000, Vol. 43
	CJ	ASTRID SASSE ET AL., (Partial) Agonist/Antagonist properties of Novel Diarylalkyl Carbamates on Histamine H ₃ Receptors, <i>Bioorganic & Medicinal Chemistry</i> , 1139-1149, 2000, Vol. 8
	CK	IWAN J. P. DE ESCH ET AL., Development of a Pharmacophore Model for Histamine H ₃ Receptor Antagonists, Using the Newly Developed Molecular Modeling Program SLATE, <i>J. Med. Chem.</i> , 1666-1674, 2001, Vol. 44
	CL	GALINA MEIER ET AL., Influence of imidazole replacement in different structural classes of histamine H ₃ -receptor antagonists, <i>European Journal of Pharmaceutical Sciences</i> , 249-259, 2001, Vol. 13
	CM	JEAN-CHARLES SCHWARTZ ET AL., Application of genomics to drug design: the example of the histamine H ₃ receptor, <i>European Neuropsychopharmacology</i> , 441-448, 2001, Vol. 11
	CN	JOACHIM APELT ET AL., Development of a New Class of Nonimidazole Histamine H ₃ Receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity, <i>J. Med. Chem.</i> , 1128-1141, 2002, Vol. 45
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.